| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Elizabeth Van Dril, Margaret Allison, Christie Schumache. Deprescribing in type 2 diabetes and cardiovascular disease: Recommendations for safe and effective initiation of glucagon-like peptide-1 receptor agonists in patients on insulin therapy. American heart journal plus : cardiology research and practice. vol 17. 2024-04-01. PMID:38559880. |
this review aims to serve as a guide for clinicians to facilitate the initiation of glp-1 receptor agonists and deintensification of insulin by providing suggested dose adjustments based on available literature. |
2024-04-01 |
2024-04-04 |
Not clear |
| Masashi Iida, Atsushi Asan. Effects of glucagon-like peptide-1 receptor agonists on spermatogenesis-related gene expression in mouse testis and testis-derived cell lines. The Journal of veterinary medical science. 2024-03-31. PMID:38556323. |
glucagon-like peptide-1 (glp-1) is an incretin released into the gastrointestinal tract after food ingestion, and stimulates insulin secretion from the beta cells of the pancreatic islets. |
2024-03-31 |
2024-04-03 |
mouse |
| Kayoko Kamemoto, Yusei Tataka, Ayano Hiratsu, Chihiro Nagayama, Yuka Hamada, Koji Kurata, Michiko Chiyoda, Machi Ito, Masashi Miyashit. Effect of vegetable consumption with chewing on postprandial glucose metabolism in healthy young men: a randomised controlled study. Scientific reports. vol 14. issue 1. 2024-03-30. PMID:38555375. |
circulating concentrations of glucose, insulin, total glucagon-like peptide-1 (glp-1) and glucose-dependent insulinotropic peptide (gip) concentrations were measured from the plasma. |
2024-03-30 |
2024-04-02 |
Not clear |
| Harunobu Nishizaki, Tomoya Kagawa, Jun Sugama, Akihiro Kobayashi, Yusuke Moritoh, Masanori Watanab. Oral SSTR5 Antagonist SCO-240 for Growth Hormone Stimulation: A Phase I Single-Dose Study in Healthy Individuals. Clinical pharmacology and therapeutics. 2024-03-29. PMID:38549435. |
the main outcome measures were safety, tolerability, pharmacokinetics, and pharmacodynamics (gallbladder contractions and levels of serum insulin and plasma glucagon-like peptide-1 (glp-1)). |
2024-03-29 |
2024-03-31 |
Not clear |
| Harunobu Nishizaki, Tomoya Kagawa, Jun Sugama, Akihiro Kobayashi, Yusuke Moritoh, Masanori Watanab. Oral SSTR5 Antagonist SCO-240 for Growth Hormone Stimulation: A Phase I Single-Dose Study in Healthy Individuals. Clinical pharmacology and therapeutics. 2024-03-29. PMID:38549435. |
no increase in gallbladder contractions or levels of insulin and glp-1 were detected. |
2024-03-29 |
2024-03-31 |
Not clear |
| Jens Juul Holst, Sten Madsbad, Kirstine Nyvold Bojsen-Møller, Carsten Dirksen, Maria Svan. New Lessons from the gut: studies of the role of gut peptides in weight loss and diabetes resolution after gastric bypass and sleeve gastrectomy. Peptides. 2024-03-29. PMID:38552903. |
it seems clear that changes in glp-1 secretion are important for insulin secretion after bypass and appear to be responsible for postbariatric hypoglycemia in glucose-tolerant individuals; however, with time the improvements in insulin sensitivity, which in turn are secondary to the weight loss, may be more important. |
2024-03-29 |
2024-04-01 |
Not clear |
| Cheol-Won Jang, Tae Yang Yu, Jin Woo Jeong, Se Eun Ha, Rajan Singh, Moon Young Lee, Seungil R. Fasting GLP-1 Levels and Albuminuria Are Negatively Associated in Patients with Type 2 Diabetes Mellitus. Journal of personalized medicine. vol 14. issue 3. 2024-03-28. PMID:38541022. |
glucagon-like peptide-1 (glp-1) is an incretin hormone known for its pivotal role in enhancing insulin secretion and reducing glucagon release from the pancreas. |
2024-03-28 |
2024-03-30 |
human |
| Haoran Jiang, Linquan Zan. GLP-1/GLP-1RAs: New Options for the Drug Treatment of NAFLD. Current pharmaceutical design. vol 30. issue 2. 2024-03-27. PMID:38532322. |
glucagon-like peptide-1 (glp-1) is an enteropeptide hormone that inhibits glucagon synthesis, promotes insulin secretion, and delays gastric emptying. |
2024-03-27 |
2024-03-29 |
Not clear |
| Nitin J Deshmukh, M S Kalshetti, Mohan Patil, Pankaj Autade, Ganesh V Sangl. Exploring the modulatory effects of sotagliflozin on dyslipidemia in mice: The role of glucagon, fibroblast growth factor 21 and glucagon-like peptide 1. Clinical and experimental pharmacology & physiology. vol 51. issue 5. 2024-03-25. PMID:38527859. |
during an oral fat tolerance test in mice, sotagliflozin substantially increased glp-1 and insulin concentrations. |
2024-03-25 |
2024-03-28 |
mouse |
| Karsten Buschard, Knud Josefsen, Lars Krogvold, Ivan Gerling, Knut Dahl-Jørgensen, Flemming Pocio. Influence of sphingolipid enzymes on blood glucose levels, development of diabetes, and involvement of pericytes. Diabetes/metabolism research and reviews. vol 40. issue 3. 2024-03-22. PMID:38517704. |
furthermore, we examined islet pericytes for sulfatide, and beta-cell receptors for glp-1, both of which are related to the insulin production. |
2024-03-22 |
2024-03-25 |
Not clear |
| Soraia Filipa Tavares Pinto, Hélder Almeida Santos, Bruno Filipe Carmelino Cardoso Sarment. New insights into nanomedicines for oral delivery of glucagon-like peptide-1 analogs. Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology. vol 16. issue 2. 2024-03-19. PMID:38500351. |
glp-1 analogs trigger insulin secretion and suppress glucagon release in a glucose-dependent manner thereby, reducing the risk of hyperglycemia. |
2024-03-19 |
2024-03-21 |
Not clear |
| Hiroki Noguchi, Takeshi Ikenaga, Shota Ueno, Chieko Kohashi, Yasuhiro Matsumura, Yusuke Kakumoto, Noriyuki Kohda, Hiroshi Hara, Tohru Hir. Effect of Single Oral Coingestion of GABA and Malic Acid on Postprandial GLP-1, Glucose, and Insulin Responses in Healthy Volunteers: A Randomized, Double-Blind, Placebo-Controlled, Crossover Study. Molecular nutrition & food research. 2024-03-15. PMID:38487986. |
effect of single oral coingestion of gaba and malic acid on postprandial glp-1, glucose, and insulin responses in healthy volunteers: a randomized, double-blind, placebo-controlled, crossover study. |
2024-03-15 |
2024-03-17 |
human |
| Hiroki Noguchi, Takeshi Ikenaga, Shota Ueno, Chieko Kohashi, Yasuhiro Matsumura, Yusuke Kakumoto, Noriyuki Kohda, Hiroshi Hara, Tohru Hir. Effect of Single Oral Coingestion of GABA and Malic Acid on Postprandial GLP-1, Glucose, and Insulin Responses in Healthy Volunteers: A Randomized, Double-Blind, Placebo-Controlled, Crossover Study. Molecular nutrition & food research. 2024-03-15. PMID:38487986. |
this study examines whether coingestion of γ-aminobutyric acid (gaba) and malic acid (ma) before meals enhances glucagon-like peptide-1 (glp-1) secretion, and which affects subsequent insulin and glycemic responses in humans. |
2024-03-15 |
2024-03-17 |
human |
| Christopher Bannon, Claire Meek, Frank Reimann, Fiona M Gribbl. Fasting and Post Prandial Pancreatic and Enteroendocrine Hormone Levels in Obese and Non-Obese Participants. Peptides. 2024-03-15. PMID:38490484. |
participants: with healthy bmi (n=15), overweight bmi (n=29) and obesity (n=161) had samples taken fasting and 30min post mixed liquid meal for analysis of glucagon-like peptide-1 (glp-1), pyy, glucose-dependent insulinotropic polypeptide (gip), insulin and glucagon. |
2024-03-15 |
2024-03-18 |
human |
| Dorte B Zilstorff, Michael M Richter, Jens Hannibal, Henrik L Jørgensen, Henriette P Sennels, Nicolai J Wewer Albrechtse. Secretion of glucagon, GLP-1 and GIP may be affected by circadian rhythm in healthy males. BMC endocrine disorders. vol 24. issue 1. 2024-03-14. PMID:38481208. |
glucagon-like peptide-1 (glp-1) and glucose-dependent insulinotropic polypeptide (gip) are secreted from gut endocrine cells during meals and control glucose homeostasis by potentiating insulin secretion and inhibiting food intake. |
2024-03-14 |
2024-03-16 |
Not clear |
| Adam G Tabak, Peter Kempler, Cristian Guja, Roy Eldor, Martin Haluzik, Tomasz Klupa, Nikolaos Papanas, Anca Pantea Stoian, Boris Mankovsk. Expert Opinion on Current Trends in the Use of Insulin in the Management of People with Type 2 Diabetes from the South-Eastern European Region and Israel. Diabetes therapy : research, treatment and education of diabetes and related disorders. 2024-03-13. PMID:38472626. |
despite an increase in the use of glucagon-like peptide-1 receptor agonists (glp-1 ras), the experts urged timely insulin initiation for inadequate glycaemic control in pwt2d. |
2024-03-13 |
2024-03-15 |
Not clear |
| Yafei Jiang, Jin Yang, Li Xia, Tianjiao Wei, Xiaona Cui, Dandan Wang, Zirun Jin, Xiafang Lin, Fei Li, Kun Yang, Shan Lang, Ye Liu, Jing Hang, Zhe Zhang, Tianpei Hong, Rui We. Gut microbiota-tryptophan metabolism-GLP-1 axis participates in β-cell regeneration induced by dapagliflozin. Diabetes. 2024-03-12. PMID:38471012. |
notably, l-tryptophan upregulated the mrna level of glp-1 production-related genes (gcg and pcsk1) expression and promoted glp-1 secretion in cultured mouse intestinal l-cells, and it increased supernatant insulin level in primary human islets, which was eliminated by gpr142 antagonist. |
2024-03-12 |
2024-03-15 |
mouse |
| Yafei Jiang, Jin Yang, Li Xia, Tianjiao Wei, Xiaona Cui, Dandan Wang, Zirun Jin, Xiafang Lin, Fei Li, Kun Yang, Shan Lang, Ye Liu, Jing Hang, Zhe Zhang, Tianpei Hong, Rui We. Gut microbiota-tryptophan metabolism-GLP-1 axis participates in β-cell regeneration induced by dapagliflozin. Diabetes. 2024-03-12. PMID:38471012. |
transplantation of fecal microbiota from dapagliflozin-treated mice, supplementation of l-tryptophan or treatment with dapagliflozin upregulated l-tryptophan, glp-1, and insulin or c-peptide level, and promoted β-cell regeneration in db/db mice. |
2024-03-12 |
2024-03-15 |
mouse |
| Chao Song, Peixuan Hu, Renpeng Peng, Feng Li, Zhong Fang, Yong X. Bioenergetic dysfunction in the pathogenesis of intervertebral disc degeneration. Pharmacological research. 2024-02-28. PMID:38417775. |
correcting the global metabolic disorders such as insulin or glp-1 receptor agonist administration is beneficial for diabetes associated ivd degeneration. |
2024-02-28 |
2024-03-02 |
human |
| Xin Jiang, Ji Li, Xiaohui Yao, Hao Ding, Aihong Gu, Zhen Zho. Neuroprotective effects of dipeptidyl peptidase 4 inhibitor on Alzheimer's disease: a narrative review. Frontiers in pharmacology. vol 15. 2024-02-26. PMID:38405664. |
beyond dpp4i's benefits in alleviating insulin resistance and glucose-lowering, underlying mechanisms for the potential neuroprotection with dpp4i medications were categorized into the following sections: (ferrari et al., physiol rev, 2021, 101, 1,047-1,081): the benefits of dpp4is on directly ameliorating the burden of β-amyloid plaques and reducing the formation of neurofibrillary tangles; dpp4i increasing the bioactivity of neuroprotective dpp4 substrates including glucagon-like peptide-1 (glp-1), glucose-dependent insulinotropic peptide (gip), and stromal-derived factor-1α (sdf-1α) etc. |
2024-02-26 |
2024-02-28 |
Not clear |